• Olive Biophenols Reduce Aβ42 Pathology in AD Models

  2026-08-26

  The reference study links olive-derived biophenols with reduced Aβ42 aggregation, oxidative stress, and plaque deposition across SH-SY5Y cells and APPswe/PS1dE9 mice. Its main contribution is a connected in vitro–in vivo design that evaluates both direct anti-amyloid activity and protection from Aβ42-associated toxicity.

• CHIR 99021 Trihydrochloride in Organoid Assays

  2026-08-26

  CHIR 99021 trihydrochloride is a potent GSK-3 inhibitor for dissecting stemness, differentiation, and metabolic signaling. This guide translates recent human intestinal organoid findings into practical assay-design decisions, emphasizing dose logic, reversible state control, and biologically meaningful readouts.

• Dose- and Time-Dependent Ibotenic Acid Toxicity

  2026-08-25

  A 2026 mouse study provides an integrated analysis of ibotenic acid toxicity across behavioral, biochemical, histological, and immunohistochemical endpoints. Its findings distinguish reversible early responses from severe high-dose injury and offer practical guidance for interpreting ibotenic acid exposure in toxicology and neuroscience research.

• Go 6983: Pan-PKC Inhibitor Workflow Guide

  2026-08-25

  Learn how to deploy Go 6983 in PKC signaling pathway research, phorbol ester challenge models, cancer progression studies, and exploratory developmental assays. This guide emphasizes dose logic, metabolic readouts, controls, and troubleshooting so broad PKC inhibition can be separated from cytotoxicity or model-specific effects.

• Ginsenosides Protect Lung and Kidney From Hypoxia

  2026-08-24

  A 2024 Frontiers in Pharmacology study shows that ginsenosides reduce acute high-altitude hypoxia injury in rat lung and kidney tissues while improving blood, inflammatory, oxidative-stress, and hemorheological measures. Its main contribution is the integration of tissue-level injury data with PHD2/HIF-1α/EPO pathway analysis, providing a mechanistic framework for evaluating ginseng-derived protection in hypoxia models.

• Bestatin (Ubenimex): Assay Workflows and Uses

  2026-08-24

  Bestatin, also known as Ubenimex, supports controlled aminopeptidase activity measurement, cancer research, and multidrug resistance studies. This practical guide connects enzyme assays with cell-based validation, highlighting solvent handling, selectivity controls, and the limits of translating bestatin-related parasite findings to new models.

• Midecamycin for Reproducible Antibacterial Assays

  2026-08-23

  Midecamycin is an acetoxy-substituted macrolide antibiotic suited to Gram-positive susceptibility testing, resistance profiling, and mechanism-focused microbiology workflows. This guide translates its ribosomal target, solvent limitations, MIC range, and historical macrolide assay methods into practical setup, optimization, and troubleshooting decisions.

• Harpagoside Targets EGFR-TKI Resistance in Lung Cancer

  2026-08-22

  The 2025 Journal of Functional Foods study shows that harpagoside can increase the sensitivity of EGFR-mutant lung adenocarcinoma models to gefitinib and paclitaxel by suppressing Nrf2-associated survival programs. Its most important contribution is the integration of resistance biology, epithelial-to-mesenchymal transition, apoptosis, ferroptosis, metastasis, and in vivo validation into a single mechanistic framework.

• G-15 Workflow for GPR30 Signaling Studies

  2026-08-22

  G-15 is a selective G protein-coupled estrogen receptor antagonist for separating GPR30 signaling from classical ERα and ERβ responses. This practical guide connects concentration planning, intracellular calcium mobilization, PI3K/Akt pathway modulation, osteoblast assays, and troubleshooting into a reproducible workflow.

• Angiotensin II: Protocol and QC Guide

  2026-08-21

  Angiotensin II (SKU A1042) provides the defined octapeptide Asp-Arg-Val-Tyr-Ile-His-Pro-Phe for controlled receptor-signaling, oxidative-stress, vascular remodeling, and hypertension mechanism studies. This guide covers preparation, dosing context, assay controls, and troubleshooting; the reagent is for scientific research only and not for diagnostic, therapeutic, or clinical use.

• Topotecan in Recurrent Small Cell Lung Cancer

  2026-08-20

  This clinical update established Topotecan as a meaningful treatment option for recurrent small cell lung cancer by synthesizing evidence from phase II studies and a randomized comparison with CAV chemotherapy. Its central contribution was to show activity in both chemosensitive and refractory relapse, while emphasizing symptom palliation, manageable toxicity, dose optimization, and the emerging role of oral treatment.

• Luminescent ATP Detection Assay Kit in Hepatocytes

  2026-08-20

  Connect mitochondrial injury to measurable energy failure with a gentle, luminescent workflow for cells, tissues, and biochemical samples. The assay combines a 1 nM–10 μM dynamic range with stable signal collection and lysates that can support downstream protein analysis.

• Angiotensin 1/2 (1-6): Research Guide

  2026-08-19

  Angiotensin 1/2 (1-6) is the Asp-Arg-Val-Tyr-Ile-His hexapeptide used in renin-angiotensin system research. Its product specifications support controlled cardiovascular and renal assays, while 2025 evidence identifies Ang (1-6) as an angiotensin fragment that can enhance spike–AXL binding in vitro.

• D-Luciferin Workflows for Tumor Bioluminescence

  2026-08-19

  D-Luciferin converts firefly luciferase activity into a practical readout for promoter activity, intracellular ATP quantification, and longitudinal tumor burden assessment. This workflow-focused guide shows how to apply the substrate to tumor-targeted genetic engineering studies while separating reporter signal from immune-infiltration and treatment-response claims.

• Macrophage–Adipoq+ Cells in Staphylococcal Osteomyelitis

  2026-08-18

  The reference study identifies a macrophage–Adipoq+ precursor cell circuit that converts local inflammation into fibrotic vascular exclusion around Staphylococcus aureus abscesses in bone marrow. Its genetic and pharmacological experiments suggest that disrupting AREG–EGFR–mTOR–YAP signaling can improve perfusion, antibiotic delivery, and bacterial clearance.

7897 records 1/527 page Next 12345 下5页 Last page